Sameet Chavan, Chief Analyst-Technical Derivatives at Angel Broking Pvt Ltd, says although there is no sign of a reversal, one should not be too gung-ho or complacent with the current momentum.

Private sector filling up the vacuum in healthcare facilities: Wockhardt

After a scathing report from the National Pharmaceutical Pricing Authority (NPPA) highlighting huge margin mark ups in corporate hospital Fortis' in patient bills, there has been a growing call for regulating private hospitals. But is it feasible? On the side-lines of a book launch, Wockhardt Hospital’s Chairman Habil Khorakiwala said government is abdicating its responsibility by just expecting to regulate private sector.

Aim to become a research-based co in 10 years; no plans to sell assets: Wockhardt

Although they have no plans to sell assets to raise money, there is an enabling board resolution in place to raise money of about Rs 1000 crore, said Habil F Khorakiwala, Founder, Wockhardt.

Hindustan Tin Works expect to cross Rs 300 crore topline in FY18

Hindustan Tin Works has gained about 25 percent in the last 3 months. It's a 58 year old company. In an interview to CNBC-TV18, Sanjay Bhatia, MD of the company spoke about the latest happenings in the company and his outlook going ahead.

Will continue to do well in UK & Indian markets: Wockhardt

In an interview to CNBC-TV18, Habil F Khorakiwala, Founder, Chairman & Group CEO of Wockhardt spoke about the latest happenings in his company and sector.

Cash ban, Brexit weigh heavy; expect normalcy in Q4: Wockhardt

Speaking to CNBC-TV18, Habil Khorakiwala, founder, chairman and CEO of Wockhardt said that due to demonetisation and the translational loss in pound due to Brexit lead to weak earnings this quarter.

No scope of US intervention in Indian pharma cos: Wockhardt

Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.

Pharma sector sales down 10-12%, pain to ease by Jan: Wockhardt

The pharmaceutical industry did suffer some set back with sales declining about 10-12 percent since demonetisation. However, Habil F Khorakiwala, Founder, Chairman & Group CEO of Wockhardt feels the impact will last only until January at the most as cash availability is improving.

CP Pharma under FDA lens, will reply in 3 weeks: Wockhardt Chief

In a blow to Wockhardt, the US FDA has issued a warning letter to company's US subsidiary CP Pharma.

Wockhardt receives US FDA's establishment inspection report

Anand Rathi's channel checks indicate EIR is in place for two facilities, Waluj and Chikalthana and implies positive step towards resolution of regulatory trends.

Aim is to prevent rampant use of antibiotics: P Lilladher

Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

R&D tax deduction unlikely to impact Wockhardt: CEO

In an interview with CNBC-TV18, Khorakiwala said Wockhardt will maintain a double digit growth target for FY17 and expects Indian operations to grow 15-20 percent while UK operations should grow within 15 percent.

See double-digit sales growth across markets in FY17: Wockhardt

Habil F Khorakiwala, founder, chairman and group CEO of Wockhardt says the company has replied to US food and drug administration (FDA) on issues related to its L1, Waluj and Shendra facilities and although a few issues are pending, he hopes it will be resolved soon

All 9 USFDA observations will be resolved in 3 months: Wockhardt

Habil Khorakiwala, Founder, Chairman and Group CEO, Wockhardt says all facilities were inspected in the past six months and none of the US FDA observations are critical in nature, while adding that all these observations will be resolved in next 2-3 months

Will not do any out-licensing in near-term: Wockhardt

Habil Khorakiwala, Founder, Chairman and Group CEO, Wockhardt says US FDA granting a QIDP status to WCK 5222 drug makes it the only company globally to receive this status for its fourth drug.

Eye 15-20% revenue growth from US biz: Wockhardt

Habil F Khorakiwala, founder and chairman, Wockhardt, says the recent recall is a part of abundant caution and the company will be able to resolve the issues soon.

No grave observations made in USFDA Waluj visit: Wockhardt

Wockhardt founder and chairman Habil F Khorakiwala says the company has also invited the regulator to visit the company‘s Chikhalthana unit to rule out any inconsistencies.

Meet the Khorakiwalas: Gen-Next promoters of Wockhardt

Wockhardt has had a fair share of difficult times too. In 2008, the pharma company‘s net worth had eroded to near bankruptcy. Global financial crisis and major foreign exchange losses had hurt it as well. To tide over the crisis, the company decided to go in for CDR in 2009.

See capex of Rs 500cr in next 3-4 yrs: Wockhardt Hospitals

On his plans for the foreseeable future, Habil Khorakiwala, chairman, Wockhardt Hospitals rules out any strategic partnership.

Will take 2-2.5 yrs for phase-3 clinical trails: Wockhardt

The QIDP status will allow fast tracking of the drug application from the USFDA and 5-year extension for the drug patents in the US.

India's pharma industry seeing rapid growth: Wockhardt

According to Habil F Khorakiwala, India is becoming a research and manufacturing hub for global pharmaceutical generic companies and the Indian companies that have well established base in the generic space like Stride transaction are getting high valuation.

Need to be watchful of FDA import alert pattern: Dandekar

Drug-maker Wockhardt has fallen foul of the US drug regulator once again and this time, the focus is on its Chikalthana plant.

Taking corrrective measures on regulatory issues: Wockhardt

Paracetamol is a very important anti-fever and painkiller, which has a large domestic production. India consumes about 10,000 tonnes of the drug in one year, says Dr Habil F Khorakiwala of Wockhardt .

Q2 earnings hit by recent regulatory actions: Wockhardt

As the drug regulators tighten their noose, Wockhardt stock has been volatile and investors are wary of the company's recovery.

PAT boost on low debt-equity, high interest: Wockhardt

Wockhardt chairman Habil Khorakiwala explains to CNBC-TV18's Archana Shukla that the PAT will get a boost on low debt-equity ratio, and high interest rates.